Literature DB >> 30078514

Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.

Yan Xie1, Benjamin Bowe1, Ali H Mokdad2, Hong Xian3, Yan Yan4, Tingting Li5, Geetha Maddukuri6, Cheng-You Tsai3, Tasheia Floyd7, Ziyad Al-Aly8.   

Abstract

The last quarter century witnessed significant population growth, aging, and major changes in epidemiologic trends, which may have shaped the state of chronic kidney disease (CKD) epidemiology. Here, we used the Global Burden of Disease study data and methodologies to describe the change in burden of CKD from 1990 to 2016 involving incidence, prevalence, death, and disability-adjusted-life-years (DALYs). Globally, the incidence of CKD increased by 89% to 21,328,972 (uncertainty interval 19,100,079- 23,599,380), prevalence increased by 87% to 275,929,799 (uncertainty interval 252,442,316-300,414,224), death due to CKD increased by 98% to 1,186,561 (uncertainty interval 1,150,743-1,236,564), and DALYs increased by 62% to 35,032,384 (uncertainty interval 32,622,073-37,954,350). Measures of burden varied substantially by level of development and geography. Decomposition analyses showed that the increase in CKD DALYs was driven by population growth and aging. Globally and in most Global Burden of Disease study regions, age-standardized DALY rates decreased, except in High-income North America, Central Latin America, Oceania, Southern Sub-Saharan Africa, and Central Asia, where the increased burden of CKD due to diabetes and to a lesser extent CKD due to hypertension and other causes outpaced burden expected by demographic expansion. More of the CKD burden (63%) was in low and lower-middle-income countries. There was an inverse relationship between age-standardized CKD DALY rate and health care access and quality of care. Frontier analyses showed significant opportunities for improvement at all levels of the development spectrum. Thus, the global toll of CKD is significant, rising, and unevenly distributed; it is primarily driven by demographic expansion and in some regions a significant tide of diabetes. Opportunities exist to reduce CKD burden at all levels of development. Published by Elsevier Inc.

Entities:  

Keywords:  CKD burden; DALYs; age; chronic kidney disease; death; diabetes; epidemiology; global health; glomerulonephritis; hypertension; incidence; population; prevalence

Mesh:

Year:  2018        PMID: 30078514     DOI: 10.1016/j.kint.2018.04.011

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  161 in total

1.  Tissue, urine and blood metabolite signatures of chronic kidney disease in the 5/6 nephrectomy rat model.

Authors:  Munsoor A Hanifa; Martin Skott; Raluca G Maltesen; Bodil S Rasmussen; Søren Nielsen; Jørgen Frøkiær; Troels Ring; Reinhard Wimmer
Journal:  Metabolomics       Date:  2019-08-17       Impact factor: 4.290

2.  Nephrology Advanced Practitioners in the United States, 2010-2018.

Authors:  Kim Zuber; Jane Davis; Kevin F Erickson
Journal:  Clin J Am Soc Nephrol       Date:  2019-07-11       Impact factor: 8.237

3.  GFR in Healthy Aging: an Individual Participant Data Meta-Analysis of Iohexol Clearance in European Population-Based Cohorts.

Authors:  Bjørn O Eriksen; Runolfur Palsson; Natalie Ebert; Toralf Melsom; Markus van der Giet; Vilmundur Gudnason; Olafur S Indridason; Lesley A Inker; Trond G Jenssen; Andrew S Levey; Marit D Solbu; Hocine Tighiouart; Elke Schaeffner
Journal:  J Am Soc Nephrol       Date:  2020-06-04       Impact factor: 10.121

4.  Human Tissue-Resident Mucosal-Associated Invariant T (MAIT) Cells in Renal Fibrosis and CKD.

Authors:  Becker M P Law; Ray Wilkinson; Xiangju Wang; Katrina Kildey; Kurt Giuliani; Kenneth W Beagley; Jacobus Ungerer; Helen Healy; Andrew J Kassianos
Journal:  J Am Soc Nephrol       Date:  2019-06-11       Impact factor: 10.121

Review 5.  Atherosclerotic-nephropathy: an updated narrative review.

Authors:  Mariadelina Simeoni; Silvio Borrelli; Carlo Garofalo; Giorgio Fuiano; Ciro Esposito; Alessandro Comi; Michele Provenzano
Journal:  J Nephrol       Date:  2020-04-08       Impact factor: 3.902

6.  [Association of metabolic syndrome with chronic kidney disease in premenopausal and postmenopausal women].

Authors:  Weicheng Xu; Chijian Li; Ge Qian; Yuxiang Huang; Liqin Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

7.  Genetics of kidney traits in worldwide populations: the Continental Origins and Genetic Epidemiology Network (COGENT) Kidney Consortium.

Authors:  Nora Franceschini; Andrew P Morris
Journal:  Kidney Int       Date:  2020-07       Impact factor: 10.612

8.  Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease.

Authors:  Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin
Journal:  Kidney Int       Date:  2020-06-20       Impact factor: 10.612

9.  Association of Longitudinal Trajectories of Systolic BP with Risk of Incident CKD: Results from the Korean Genome and Epidemiology Study.

Authors:  Young Su Joo; Changhyun Lee; Hyung Woo Kim; Jonghyun Jhee; Hae-Ryong Yun; Jung Tak Park; Tae Ik Chang; Tae-Hyun Yoo; Shin-Wook Kang; Seung Hyeok Han
Journal:  J Am Soc Nephrol       Date:  2020-08-05       Impact factor: 10.121

Review 10.  Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.

Authors:  Jinnie J Rhee; Meg J Jardine; Glenn M Chertow; Kenneth W Mahaffey
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.